Lantern Pharma logo

Lantern Pharma Share Price Today

(NASDAQ: LTRN)

Lantern Pharma share price is $4.8 & ₹418.06 as on 5 Feb 2025, 2.30 'hrs' IST

$4.8

0.13

(2.78%)

Market is closed - opens 8 PM, 05 Feb 2025

View live Lantern Pharma share price in Dollar and Rupees. Guide to invest in Lantern Pharma stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Lantern Pharma, along with analyst recommendations, forecasts, and comprehensive financials.

Lantern Pharma share price movements

  • Today's Low: $4.64
    Today's High: $5.04

    Day's Volatility :7.93%

  • 52 Weeks Low: $2.79
    52 Weeks High: $11.99

    52 Weeks Volatility :76.73%

Lantern Pharma (LTRN) Returns

PeriodLantern Pharma IncSector (Health Care)Index (Russel 2000)
3 Months
41.09%
0.5%
0.0%
6 Months
15.88%
-2.3%
0.0%
1 Year
11.72%
3.8%
0.0%
3 Years
-31.12%
11.4%
-11.7%

Lantern Pharma (LTRN) Key Statistics

in dollars & INR

Previous Close
$4.67
Open
$4.64
Today's High
$5.0399
Today's Low
$4.64
Market Capitalization
$53.4M
Today's Volume
$44.5K
52 Week High
$11.99
52 Week Low
$2.79
Revenue TTM
$0.0
EBITDA
$-19.5M
Earnings Per Share (EPS)
$-1.78
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-44.82%

How to invest in Lantern Pharma Stock (LTRN) from India?

It is very easy for Indian residents to invest directly in Lantern Pharma from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Lantern Pharma stock in both Indian Rupees (INR) and US Dollars (USD). Search for Lantern Pharma or LTRN on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Lantern Pharma or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Lantern Pharma shares which would translate to 0.181 fractional shares of Lantern Pharma as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Lantern Pharma, in just a few clicks!

Returns in Lantern Pharma (LTRN) for Indian investors in Rupees

The Lantern Pharma stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Lantern Pharma investment value today

Current value as on today

₹1,19,697

Returns

₹19,697

(+19.7%)

Returns from Lantern Pharma Stock

₹14,833 (+14.83%)

Dollar Returns

₹4,865 (+4.86%)

Indian investors sentiment towards Lantern Pharma (LTRN)

-44%

Period: Jan 5, 2025 to Feb 4, 2025. Change in 30 Days versus previous period

Search interest for Lantern Pharma Stock from India on INDmoney has decreased by -44% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Lantern Pharma

  • Vanguard Group Inc

    3.37%

  • CM Management, LLC

    1.72%

  • Goss Wealth Management LLC

    1.27%

  • Geode Capital Management, LLC

    0.81%

  • Renaissance Technologies Corp

    0.78%

  • BlackRock Inc

    0.38%

Analyst Recommendation on Lantern Pharma

Buy

    75%Buy

    25%Hold

    0%Sell

Based on 8 Wall street analysts offering stock ratings for Lantern Pharma(by analysts ranked 0 to 5 stars)

Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
2
2
2
Sell
0
0
0

Analyst Forecast on Lantern Pharma Stock (LTRN)

What analysts predicted

Upside of 327.08%

Target:

$20.50

Current:

$4.80

Insights on Lantern Pharma Stock (Ticker Symbol: LTRN)

  • Price Movement

    In the last 1 month, LTRN stock has moved up by 24.9%
  • LTRN vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 58.6% return, outperforming this stock by 48.7%
  • LTRN vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 88.8% return, outperforming this stock by 119.5%

Lantern Pharma Technicals Summary

Sell

Neutral

Buy

Lantern Pharma is currently in a neutral trading position according to technical analysis indicators.

Lantern Pharma (LTRN) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Lantern Pharma Inc logo
11.46%
15.88%
11.72%
-31.12%
-68.76%
Biontech Se logo
-0.32%
51.19%
24.81%
-30.66%
288.02%
Regeneron Pharmaceuticals, Inc. logo
-6.9%
-37.55%
-28.89%
7.15%
74.63%
Vertex Pharmaceuticals Incorporated logo
16.87%
0.96%
13.03%
93.36%
95.94%
Alnylam Pharmaceuticals, Inc. logo
17.76%
5.53%
59.46%
84.7%
118.8%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Lantern Pharma Inc logo
NA
NA
NA
-1.93
-0.45
-0.28
NA
3.82
Biontech Se logo
160.8
NA
0.04
-3.32
-0.02
-0.01
NA
79.73
Regeneron Pharmaceuticals, Inc. logo
16.64
16.64
1.08
44.92
0.17
0.07
NA
272.04
Vertex Pharmaceuticals Incorporated logo
32.84
NA
1.21
0.49
-0.03
0.12
NA
60.65
Alnylam Pharmaceuticals, Inc. logo
NA
NA
-0.49
-0.18
-15.01
-0.03
NA
0.25
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Lantern Pharma Inc logo
Buy
$53.4M
-68.76%
NA
0.0%
Biontech Se logo
Buy
$29.7B
288.02%
160.8
-15.36%
Regeneron Pharmaceuticals, Inc. logo
Buy
$74.0B
74.63%
16.64
33.61%
Vertex Pharmaceuticals Incorporated logo
Buy
$118.9B
95.94%
32.84
-4.51%
Alnylam Pharmaceuticals, Inc. logo
Buy
$35.0B
118.8%
NA
-15.86%

About Lantern Pharma

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
Organization
Lantern Pharma
Employees
21
CEO
Mr. Panna Sharma PH.D.
Industry
Commercial Services

Management People of Lantern Pharma

NameTitle
Mr. Panna Sharma PH.D.
President, CEO & Director
Mr. David R. Margrave
CFO & Secretary
Dr. Kishor Gopaldas Bhatia Ph.D.
Chief Scientific Officer & Scientific Consultant
Nicole Leber
Investor Relations Associate, Finance & Administrative Coordinator
Dr. Peter L. Nara D.V.M., M.S., Ph.D.
Co-Founder & Advisor
Mr. Ernest Kitt B.S., M.S
Head of Clinical Operations
Dr. Marc C. Chamberlain M.D.
Chief Medical Officer of Starlight Therapeutics

Important FAQs about investing in LTRN Stock from India :

What is Lantern Pharma share price today?

Lantern Pharma share price today stands at $4.80, Open: $4.64 ; Previous Close: $4.67 ; High: $5.04 ; Low: $4.64 ; 52 Week High: $11.99 ; 52 Week Low: $2.79.

The stock opens at $4.64, after a previous close of $4.67. The stock reached a daily high of $5.04 and a low of $4.64, with a 52-week high of $11.99 and a 52-week low of $2.79.

Can Indians buy Lantern Pharma shares?

Yes, Indians can invest in the Lantern Pharma (LTRN) from India.

With INDmoney, you can buy Lantern Pharma at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Lantern Pharma at zero transaction cost.

How can I buy Lantern Pharma shares from India?

It is very easy to buy Lantern Pharma from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Lantern Pharma (LTRN) be purchased?

Yes, you can buy fractional shares of Lantern Pharma with INDmoney app.

What are the documents required to start investing in Lantern Pharma stocks?

To start investing in Lantern Pharma, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Lantern Pharma Stock (LTRN)?

Today’s highest price of Lantern Pharma (LTRN) is $5.04.

Today’s lowest price of Lantern Pharma (LTRN) is $4.64.

What is today's market capitalisation of Lantern Pharma?

Today's market capitalisation of Lantern Pharma LTRN is 53.4M

What is the 52 Week High and Low Range of Lantern Pharma Stock (LTRN)?

  • 52 Week High

    $11.99

  • 52 Week Low

    $2.79

What are the historical returns of Lantern Pharma (LTRN)?

  • 1 Month Returns

    11.46%

  • 3 Months Returns

    15.88%

  • 1 Year Returns

    11.72%

  • 5 Years Returns

    -68.76%

Who is the Chief Executive Officer (CEO) of Lantern Pharma ?

Mr. Panna Sharma PH.D. is the current Chief Executive Officer (CEO) of Lantern Pharma.